Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
B Wang, N Zaidi, LZ He, L Zhang, JMY Kuroiwa… - Breast cancer …, 2012 - Springer
Introduction Given their relative simplicity of manufacture and ability to be injected
repeatedly, vaccines in a protein format are attractive for breast and other cancers. However …
repeatedly, vaccines in a protein format are attractive for breast and other cancers. However …
[HTML][HTML] A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles
PK Chattopadhyay, J Yu, M Roederer - Nature medicine, 2005 - nature.com
Recently activated, but not resting, CD4+ T cells express CD154, providing costimulatory
signals to B cells and antigen-presenting cells (APCs). Therefore, de novo CD154 …
signals to B cells and antigen-presenting cells (APCs). Therefore, de novo CD154 …
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
SB Lacher, J Dörr, GP de Almeida, J Hönninger… - Nature, 2024 - nature.com
Abstract Cancer-specific TCF1+ stem-like CD8+ T cells can drive protective anticancer
immunity through expansion and effector cell differentiation,,–; however, this response is …
immunity through expansion and effector cell differentiation,,–; however, this response is …
CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer
YJ Lee, JY Kim, SH Jeon, H Nam, JH Jung… - Science …, 2022 - science.org
Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors
(ICIs) are only efficacious for a subset of patients. To gain a better understanding of the …
(ICIs) are only efficacious for a subset of patients. To gain a better understanding of the …
[HTML][HTML] Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not …
HER2-targeted monoclonal antibodies improve the outcome for advanced breast cancer
patients; however, resistance to therapy is still frequent. Epitope masking and steric …
patients; however, resistance to therapy is still frequent. Epitope masking and steric …
[HTML][HTML] CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
L Diehl, AT den Boer, SP Schoenberger… - Nature medicine, 1999 - nature.com
The outcome of antigen recognition by naive CD8+ cytotoxic T lymphocytes (CTLs) in the
periphery is orchestrated by CD4+ T-helper cells, and can either lead to priming or …
periphery is orchestrated by CD4+ T-helper cells, and can either lead to priming or …
[HTML][HTML] A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Evidence from mouse chronic viral infection models suggests that CD8+ T cell subsets
characterized by distinct expression levels of the receptor PD-1 diverge in their state of …
characterized by distinct expression levels of the receptor PD-1 diverge in their state of …
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Metastatic disease remains the primary cause of death for patients with breast cancer. The
different steps of the metastatic cascade rely on reciprocal interactions between cancer cells …
different steps of the metastatic cascade rely on reciprocal interactions between cancer cells …
[HTML][HTML] HER kinase inhibition in patients with HER2-and HER3-mutant cancers
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are
found in a wide range of cancers. Preclinical modelling suggests that a subset of these …
found in a wide range of cancers. Preclinical modelling suggests that a subset of these …
[HTML][HTML] cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity
Conventional type 1 dendritic cells (cDC1) are thought to perform antigen cross-
presentation, which is required to prime CD8+ T cells,, whereas cDC2 are specialized for …
presentation, which is required to prime CD8+ T cells,, whereas cDC2 are specialized for …